Special channel feed – Endpoints News

SIGN UP

Special channel feed

2020’s NDA list is packed with commercial firsts — from historic to haphazard. Have we reached a tipping point?

3 years ago

Special report: Twenty extraordinary women blazing trails in biopharma R&D — Covid-19 and beyond

3 years ago

The Endpoints 11: Here are some of the most promising startups in biotech. And Covid-19 isn't going to stop them

3 years ago

The 20 under 40: Inside the next generation of biopharma leaders

3 years ago

The E100 biotech survey: Execs are hunkering down for the pandemic, worried about longterm fallout — but eager to see biopharma make a difference

3 years ago

The top 10 biopharma pipeline blowups, setbacks and snafus for H2 2019

3 years ago

Here are the 52 new drugs approved by the FDA in 2019. Who won? Who lost? And who just survived to 2020?

4 years ago

Special report: Twenty extraordinary women in biopharma R&D who worked their way to the top

4 years ago

The $102B club: The top 15 R&D spenders in the global biopharma business — 2019 edition

4 years ago

The top 10 pipeline blowups, setbacks and snafus for H1 2019

4 years ago

Biotech execs predict big M&A deals ahead as mood shifts in wake of a 2018 hangover — Endpoints 100

4 years ago

The top 10 pipeline blowups, setbacks and snafus for H2 2018

4 years ago

The 2018 breakdown on a chart-topping set of new drug approvals — and the 5 big things we learned from it

5 years ago

The top 10 stories from Endpoints News in 2018

5 years ago

What do Martin Shkreli, Gilead and Takeda have in common? They all figure prominently in the new top-20 list of the world’s most expensive drugs

5 years ago

A go-go FDA is poised to break the all-time record on new drug approvals. Is this the new standard for biopharma success?

5 years ago

Global reach: The top 25 biopharma companies in the world

5 years ago

The biotech mood at the halfway mark of 2018? Boisterous, focusing more attention on China and looking for accelerated progress

5 years ago

Who are the most productive drug developers in biopharma? Our top-20 list has lots of surprises

5 years ago

Top 10 pipeline blowups, setbacks and snafus in H1 2018

5 years ago

12 top China VCs you need to know who are making a transpacific splash (Part 2)

5 years ago

The under-40s: How does the next generation of biopharma executives view the future?

5 years ago

Elephants can't jump? IDEA's Mike Rea says some Big Pharma players are crushing old beliefs

5 years ago

12 blockbusters: The surging list of $1B-plus drugs rolling out on the market this year might surprise you

5 years ago

First page Previous page 123 Next page Last page

All of the news, delivered with full-text to your inbox. For professionals discovering, developing, and marketing biopharmaceutical drugs.

SIGN UP NOW

Subscribe to Endpoints News